Incyte Corporation Stock News

Evaluate the expected performance of Incyte (INCY) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics

Incyte (INCY) is likely to rebound in 2024 on the solid growth of Opzelura and additional label expansions.

Sector components forecast to show the biggest earnings year-over-year earnings improvement include Humana Inc. NYSE: HUM, Elevance Health Inc. NYSE: ELV, Incyte Corp. NASDAQ: INCY, Insulet Corp.

Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.

Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid

As technology advances in our era, biotechnology is not far behind. Modern day medical advancements are impressive, and the company's making these strides have incredible results to show for it.

Shares of the biopharmaceutical company are on pace for their best day in more than six years.

When it comes to biotech stocks, I usually like to take a “Goldilocks” approach. This involves investing in biotech companies that have one or more promising drugs in mid-to-late stage clinical tr

Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to

Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance for 2023.

Incyte Corporation (NASDAQ:INCY ) Q3 2023 Earnings Call Transcript October 31, 2023 8:00 AM ET Company Participants Ben Strain - Head of Investor Relations Herve Hoppenot - President and Chief Executi

Incyte reported a third-quarter profit on Tuesday that beat analysts' estimates as lower costs helped offset weak sales of its blood cancer drug Jakafi.

Incyte (INCY) came out with quarterly earnings of $1.10 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $0.60 per share a year ago.

Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.

Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the treatment of adult patients with extensive nonsegmental vitiligo.